Pimping up Drugs Recovered, Superannuated and Under Exploited Drugs - An Introduction to the Basics of Drug Reprofiling

Author(s): Suzanne J. Dilly*, George S. Morris

Journal Name: Current Drug Discovery Technologies

Volume 14 , Issue 2 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Drug development has moved along way forward from the days of with doctors peddling cauldrons of herbs and spices, however, the process can still miss opportunities for full exploitation of a drug’s potential. Drug reprofiling provides a chance for an established or a forgotten drug to move into a new area of therapy, whether related to the known effects or in a completely new area. In an era of environmental awareness and spiraling costs for traditional drug development, a strategy to squeeze every benefit out of drugs with known safety, tolerability and pharmacological parameters must be a strategically sound desire. We explore examples of success in reprofiling, draw comparisons between techniques, and finally provide two examples from the Valirx plc development pipeline currently undergoing the process.

Keywords: Reprofiling, development, techniques, health economics, risperidone, cancer.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 16 April, 2017
Page: [121 - 126]
Pages: 6
DOI: 10.2174/1570163814666170117120005

Article Metrics

PDF: 35